

Home > Journal > Medicine & Healthcare > JDM

[Indexing](#) [View Papers](#) [Aims & Scope](#) [Editorial Board](#) [Guideline](#) [Article Processing Charges](#)

JDM > Vol.2 No.4, November 2012

OPEN ACCESS

Acute pancreatitis in a patient receiving sitagliptin

PDF (Size: 82KB) PP. 406-407 DOI: 10.4236/jdm.2012.24063

Author(s)

Shamael Abdulredha Sanaseeri, Awsan Mohammad Almohaini, Asrar Said Hashem

ABSTRACT

Describing a reported case of acute pancreatitis in a patient receiving sitagliptin. We present the biochemical and findings of a 60 year-old male who presented with severe abdominal pain and was found to have acute pancreatitis. This occurred one month after the commencement of sitagliptin, a dipeptidyl peptidase IV inhibitor, for the treatment of uncontrolled type 2 diabetes. Results: Pancreatic enzymes were elevated (*i.e.* amylase 204, lipase: 525.3) with a normal liver function test and a normal lipid profile. Ultrasound abdomen was unremarkable. In the absence of an identifiable cause for the patient's pancreatitis, sitagliptin was considered a potential trigger and on ceasing this agent, the patient recovered from his condition. Conclusion: Incretin-based therapy is an effective line in the treatment of type 2 diabetes mellitus. FDA issued a warning letters to the drug company because of emerging reports of acute pancreatitis in patients receiving sitagliptin. This is unfortunately not the first reported case of acute pancreatitis in a patient receiving sitagliptin and it supports the possibility that acute pancreatitis may be the effect of incretin-based therapy.

KEYWORDS

Acute Pancreatitis; Dipeptidyl Peptidase IV Inhibitor; Sitagliptin

Cite this paper

Sanaseeri, S., Almohaini, A. and Hashem, A. (2012) Acute pancreatitis in a patient receiving sitagliptin. *Journal of Diabetes Mellitus*, 2, 406-407. doi: 10.4236/jdm.2012.24063.

References

- [1] Aggio, L.L. and Drucker, D.J. (2007) Biology of incretins: GLP-1 and GIP. *Gastroenterology*, 132, 213-2157.
- [2] Kieffer, T.J. and Habener, J.F. (1999) The glucagon-like-peptides. *Endocrine Reviews*, 20, 876-913. doi: 10.1210/er.20.6.876
- [3] Dalla, M.C., Bock, G., Giesler, P.D., Serra, D.B., Ligueros Saylan, M., Foley, J.E., Camilleri, M., Toffolo, G., Cobelli, C., Rizza, R.A. and Vella, A. (2009) Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes. *Diabetes Care*, 32, 14-18. doi: 10.2337/dc08-1512
- [4] Olansky, L. (2010) "Do incretin-based therapies cause acute pancreatitis?" *Journal of Diabetes Science and Technology*, 4, 228-229.
- [5] Forsmark, C.E. and Baillie, J. (2007) AGA Institute Clinical Practice Economics Committee. AGA Institute Governing; Board AGA Institute Clinical Practice and Economics Committee; AGA Institute Governing Board. *Gastroenterology*, 132, 2022-2044. doi: 10.1053/j.gastro.2007.03.065
- [6] Forsmark, C.E. and Baillie, J. (2007) AGA Institute Clinical Practice Economics Committee. AGA Institute Governing; Board AGA Institute Clinical Practice and Economics Committee; AGA Institute Governing Board. *Gastroenterology*, 132, 2022-2044. doi: 10.1053/j.gastro.2007.03.065
- [7] Field, A.E., Coakley, E.H., Must, A., Spadano, J.L., Laird, N., Dietz, W.H., Rimm and E., Colditz, G.A. (2001) Impact of overweight on the risk of developing common chronic diseases during a 10-year

JDM Subscription

Most popular papers in JDM

About JDM News

Frequently Asked Questions

Recommend to Peers

Recommend to Library

Contact Us

Downloads: 56,062

Visits: 113,209

Sponsors >>

